Free Trial
OTCMKTS:FSNUY

Fresenius SE & Co. 11/2/2023 Earnings Report

Fresenius SE & Co. logo
$13.61 +0.00 (+0.01%)
As of 03:58 PM Eastern

Fresenius SE & Co. EPS Results

Actual EPS
$0.17
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Fresenius SE & Co. Revenue Results

Actual Revenue
$6.01 billion
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Fresenius SE & Co. Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Fresenius SE & Co.'s next earnings date is estimated for Wednesday, November 5, 2025, based on past reporting schedules.

Conference Call Resources

Fresenius SE & Co. Earnings Headlines

$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.tc pixel
See More Fresenius SE & Co. Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Fresenius SE & Co.? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fresenius SE & Co. and other key companies, straight to your email.

About Fresenius SE & Co.

Fresenius SE & Co. (OTCMKTS:FSNUY) KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.

View Fresenius SE & Co. Profile

More Earnings Resources from MarketBeat